Cerus Endovascular has announced that it has received CE mark approval for its Neqstent Coil Assisted Flow Diverter device. The flow diverter is designed to treat intracranial aneurysms and a range of morphologies, including wide-necked bifurcation and bifurcation aneurysms. Neqstent is an adjunctive intrasaccular flow diverter device that provides stable aneurysm neck coverage for the placement of embolisation coils within the sac and long-term occlusion of the aneurysm.
According to the company’s press release, commercial sales, via a controlled market release across the European Union, are expected to begin during the fourth quarter of 2020.
“Many physicians already have firsthand experience using embolisation coils, and the Neqstent will serve as an intrasaccular flow diverting device, which will work in combination with embolisation coils,” stated Stephen Griffin, president of Cerus Endovascular. “Our goal is to offer a breath of solutions for the treatment of these aneurysms. Physicians who have used the Neqstent comment on its ease of use through its controlled deliverability and deployment.”
Sam Milstein, chairman of Cerus Endovascular, added: “On behalf of the entire Cerus team, we would like to acknowledge the heroic and extraordinary sacrifices being made on a daily basis by healthcare workers, first-responders and the public at large, during this devastating pandemic. We join in the global commitment to do all that we can to battle back against the virus and assist the broader community in any way that we can.”
